News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 137
- Sources here
- 14
- Companies here
- 7
Search results
Stored financial headlines
Active search
137 matching headlines
Ticker or company: INTSMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Intensity Therapeutics (Nasdaq: INTS) will report its second quarter 2026 financial results on August 11, 2026, before the market opens. Management will host a conference call and live webcast at 8:00 AM Eastern Time to discuss these results and provide a corporate update. The …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics Inc (INTS) Cash Flow
This article presents the cash flow statement for Intensity Therapeutics Inc (INTS), detailing its operating, investing, and financing cash flows on a quarterly and annual basis. It includes a table with financial figures exhibiting year-over-year changes for various cash flow components. The piece also …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Intensity Therapeutics Inc (INTS), evaluating its stock based on various indicators and moving averages. It categorizes signals from these tools as Buy, Sell, or Neutral, and offers a summary of the stock's current technical status. The analysis …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030
Intensity Therapeutics Inc. (INTS) closed at $4.45 with a 0.68% increase. The company, a late-stage clinical biotechnology firm, is developing treatments for cancer with its lead product candidate, INT230-6, currently in Phase 3 trials. Analysts rate the stock as a "Buy" with a target …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading
Intensity Therapeutics (INTS) director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026. The option has an exercise price of $4.90 per share, expires on July 16, 2036, and vests in four equal annual installments beginning …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS) Proxy filing Summary
Intensity Therapeutics (INTS) has released a proxy filing summary for its upcoming virtual annual meeting on June 16, 2026. Shareholders as of April 23, 2026, will vote on proposals including the election of two directors, ratification of the auditor, and amendments to equity plans. …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS) Q1 2026 earnings summary
Intensity Therapeutics (INTS) reported a Q1 2026 net loss of $2.4 million, an improvement from Q1 2025, primarily due to reduced R&D expenses. The company ended the quarter with $10.2 million in cash, supported by recent fundraising and a new ATM facility, but faces …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90
Intensity Therapeutics, Inc. (INTS) director Emer Leahy was granted 5,500 stock options at an exercise price of $4.90 per share. These options will vest in four equal annual installments starting July 16, 2026, and will expire on July 16, 2036. This transaction reflects equity …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90
Intensity Therapeutics has granted its Chief Financial Officer, Joseph Talamo, 34,000 stock options with an exercise price of $4.90 per share. These options, which expire on July 16, 2036, will vest in four equal annual installments starting July 16, 2027, contingent on his continued …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics has restarted patient treatment in its Phase 2 INVINCIBLE-4 Study for triple-negative breast cancer (TNBC) in Switzerland, after a temporary pause to address skin irritation issues. The trial, using INT230-6 before standard-of-care immunotherapy-chemotherapy, aims to improve pathological complete response rates in patients …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%